The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease—A report from Central and Eastern Europe

  1. Justyna D. Kowalska
  2. Kerstin Kase
  3. Anna Vassilenko
  4. Arjan Harxhi
  5. Botond Lakatos
  6. Gordana Dragović Lukić
  7. Antonija Verhaz
  8. Nina Yancheva
  9. Florentina Dumitrescu
  10. David Jilich
  11. Ladislav Machala
  12. Agata Skrzat-Klapaczyńska
  13. Raimonda Matulionyte

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.ijid.2020.12.026
  2. ScreenIT

    SciScore for 10.1101/2020.10.28.20221226: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    We have observed the difference suggesting that the cART regimen may play a role in the course of SARS-CoV-2 related disease, yet this finding needs to be interpreted with cautious due to many limitations of this work. A recent study by del Amo et al. of 236 HIV-positive persons with COVID-19 diagnosis and receiving cART in Spain, suggested a decreased risk of COVID-19 and hospitalization among persons on tenofovir disoproxil with emtricitabine as compared to other NRTI components (16). This study did not analyze other cART components. We did not see the same associations in our study, however due to a small sample we were unable to disentangle the effects of different forms of tenofovir (17). Certainly there is a risk of bias per indication reflecting that ‘healthier patients” would stay on more toxic regimen containing tenofovir disoproxil, while patients with comorbidities would be switched or prescribed tenofovir alafenamide. Such confounding should be taken into account in COVID-19 and HIV research (18). As for other cART regimens in our study the most common third component in the regimen was integrase inhibitor (47.0 %), followed by protease inhibitors (20.6 %) and non-nucleoside reverse transcriptase inhibitors (17.6 %). The difference between COVID-19 severity group was observed for the latter two. It has been indicated by other studies that neither tenofovir nor darunavir protect HIV-positive persons from acquiring SARS-CoV-2 (8, 19). In parallel, no benefit was obs...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.10.28.20221226v1 on medRxiv